Methods: The reference standard [F-19]BAY94-9172 and the new precursor (Compound 9) were obtained from the HER2 inhibitor reactions of (E)-4-methylamino-4′-hydroxystilbene (Compound 1) with methanesulfonic acid 2-[2-(2-fluoro-ethoxy)-ethoxy]-ethyl

ester (Compound 11) and methanesulfonic acid 2-[2-(2-methanesulfonyloxy-ethoxy)-ethoxy]-ethyl ester (Compound 13), respectively. The reported precursor (Compound 6) is an N-BOC-protected mesylate compound, which was obtained from Compound 9. The one-step radiosynthesis of [F-18] BAY94-9172 was carried out in the modified PET-MF-2V-IT-1 synthesizer by [F-18]fluorination of the new precursor (Compound 9) and purification with plus C18 Sep-Pak cartridges and was compared with two-step one-pot radiosynthesis using the reported precursor (Compound 6) and Sep-Pak cartridge purification.

Results: For one-step radiosynthesis, the uncorrected radiochemical yield of [F-18]BAY94-9172 was 23 +/- 3% (n=5, based on [F-18]fluoride) within 30 min and the radiochemical purity was greater than 95%. For two-step one-pot radiosynthesis, the uncorrected radiochemical yield of [F-18]BAY94-9172 was 17 +/- 2% in 45 min (n=4, based on [F-18]fluoride) with the radiochemical purity being above 95% after the Sep-Pak cartridge purification.

Conclusion: [F-19]BAY94-9172 and the two precursors

were synthesized by a short synthetic route. Compared with HPLC purification, the use of Sep-Pak purification of Danusertib [F-18]BAY94-9172 reduced the total radiosynthesis time. The one-step radiosynthesis of [F-18]BAY94-9172 is convenient and can easily be applied to the commercial PET tracer synthesizer for automated synthesis. (C) 2011 Elsevier

Inc. All rights reserved.”
“Objective: Leukocytes in allogeneic blood transfusions cause several immunomodulatory events. This before-and-after cohort study evaluated clinical outcomes after adoption of prestorage leukoreduction program for blood transfusions, with particular focus on acute kidney injury.

Methods: One thousand thirty-four consecutive patients who underwent on-pump coronary artery bypass grafting between January 2004 and December 2007 were included. the Propensity score analysis for transfusion was performed in the whole population; patients who were actually transfused were then divided according to leukoreduction. From these 2 groups, 147 pairs matched for propensity score were considered to evaluate with bivariate and multivariable analyses the effects of leukoreduction, with all-cause in-hospital mortality and morbidity as main outcomes.

Results: Unadjusted in-hospital mortalities were 6.6% for the entire cohort and 44.2% for those with acute kidney injury. In the matched population, after introduction of leukoreduction, mortality rates decreased to 5.4% (vs 11.4%) and acute kidney injury (RIFLE [Risk, Injury, Failure, Loss of function, End-stage renal disease] class R or greater) dropped from 51.7% to 41.5% (relative risk -20%, P < .045).